MedTrace Logo

China Stroke Primary Prevention Trial

NCT00794885 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20702

Last updated 2014-08-12

No results posted yet for this study

Summary

The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.

Conditions

  • Primary Hypertension

Interventions

DRUG

Enalapril/folic acid

Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.

DRUG

Enalapril maleate

Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.

Sponsors & Collaborators

  • Anhui Medical University

    collaborator OTHER

  • Shenzhen Ausa Pharmed Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Yong Huo, M.D. · The First Hospital, Beijing University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2013-08-31
Completion
2014-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00794885 on ClinicalTrials.gov